B7-H6 Antibody (2167B) [Unconjugated]

HeLa human cervical epithelial carcinoma cell line was stained with Rabbit Anti-Human B7-H6 Monoclonal Antibody (Catalog # MAB71443, filled histogram) or isotype control antibody (Catalog # MAB1050, open histogram), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # F0111). View our protocol for Staining Membrane-associated Proteins.

HEK293 human embryonic kidney cell line transfected with human B7-H6and eGFP was stained with either (A) Rabbit Anti-Human B7-H6 Monoclonal Antibody (Catalog # MAB71443) or (B) Rabbit IgG control antibody (Catalog # MAB1050) followed by APC-conjugated Goat anti-Rabbit IgG Secondary Antibody (Catalog # F0111). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow, CyTOF-ready
• Clone: 2167B
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

B7-H6 Antibody (2167B) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Human embryonic kidney cell, HEK293-derived human B7-H6 protein
  Asp25-Ser262
  Accession # Q68D85
• Specificity: Detects human B7-H6 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for B7-H6 Antibody (2167B) [Unconjugated]

• B7 homolog 6
• B7H6
• B7-H6
• DKFZp686I21167
• DKFZp686O24166
• NCR3LG1

Background

B7-H6 is a glycosylated member of the B7 family of immune co‑stimulatory proteins (1, 2). Mature human B7-H6 consists of a 238 amino acid (aa) extracellular domain (ECD) that contains one Ig-like V domain and one Ig-like C1 domain, a 21 aa transmembrane segment, and a 171 aa cytoplasmic domain that contains one ITIM, one SH2, and one SH3 motif (3). Both of the Ig-like domains carry N-linked glycosylation (4). Within the ECD, human B7-H6 shares 99%, 94%, and 87% aa sequence identity with chimpanzee, orangutan, and gibbon B7-H6, respectively, and 53%-56% with bovine, canine, and equine B7-H6. Orthologs in mouse and rat have not been identified. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells (4, 5). It does not show binding to NKp44, NKp46, or NKG2D (3, 6). Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytolysis (3). B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors (3, 7). The expression of NKp30 ligands on tumor cells correlates with tumor cell sensitivity to NKp30‑dependent cell lysis (7).

1. Zou, W. and L. Chen (2008) Nat. Rev. Immunol. 8:467.
2. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
3. Brandt, C.S. et al. (2009) J. Exp. Med. 206:1495.
4. Li, Y. et al. (2011) J. Exp. Med. 208:703.
5. Joyce, M.G. et al. (2011) Proc. Natl. Acad. Sci. 108:6223.
6. Arnon, T.I. et al. (2006) Semin. Cancer Biol. 16:348.
7. Byrd, A. et al. (2007) PLoS ONE 2:e1339.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q68D85()